Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3263 Injection, toripalimab-tpzi, 1 milligrams

J Codes (Drugs)

Also known as: toripalimab, Tuoyi, PD-1 inhibitor

Toripalimab-tpzi (Tuoyi) 1 milligram injection is a programmed death receptor-1 inhibitor used for advanced melanoma and other cancers as immunotherapy.

In Plain Language

cancer immunotherapy injection; melanoma treatment

Clinical Context

Indicated for unresectable or metastatic melanoma as a checkpoint immunotherapy. Blocks programmed death-1 pathway to enhance anti-tumor immunity. Requires monitoring for immune-related adverse events.

RVU Information

CPT J3263 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

OncologyHematology/OncologyInfusion Centers

Frequently Asked Questions

What is CPT code J3263?

CPT J3263 (Injection, toripalimab-tpzi, 1 milligrams) is a J Codes (Drugs) code. Toripalimab-tpzi (Tuoyi) 1 milligram injection is a programmed death receptor-1 inhibitor used for advanced melanoma and other cancers as immunotherapy.

How is J3263 administered?

CPT J3263 is administered by a healthcare provider, typically via injection or infusion. Indicated for unresectable or metastatic melanoma as a checkpoint immunotherapy. Blocks programmed death-1 pathway to enhance anti-tumor immunity. Requires monitoring for immune-related adverse events. It is used by Oncology, Hematology/Oncology, Infusion Centers.

When is CPT J3263 used?

Indicated for unresectable or metastatic melanoma as a checkpoint immunotherapy. Blocks programmed death-1 pathway to enhance anti-tumor immunity. Requires monitoring for immune-related adverse events.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.